Literature DB >> 28786258

The Role of Hyperbaric Oxygen Therapy in Orthopedics and Rheumatological Diseases.

Giuseppe Barilaro1, Ignazio Francesco Masala2, Renato Parracchini3, Cesare Iesu4, Giulia Caddia4, Piercarlo Sarzi-Puttini5, Fabiola Atzeni6.   

Abstract

BACKGROUND: Hyperbaric oxygen therapy (HBOT) has been investigated as a primary/adjunctive treatment for a number of injuries and medical conditions including traumatic ischemia, necrotizing soft tissue injuries, non-healing ulcers and osteoradionecrosis, but the results are controversial. There is insufficient evidence to support or reject the use of HBOT to quicken healing or to treat the established non-union of fractures. However, in patients with fibromyalgia, HBOT reduces brain activity in the posterior cortex and increases it in the frontal, cingulate, medial temporal and cerebellar cortices, thus leading to beneficial changes in brain areas that are known to function abnormally. Moreover, the amelioration of pain induced by HBOT significantly decreases the consumption of analgesic medications. In addition, HBOT has anti-inflammatory and oxygenatory effects in patients with primary or secondary vasculitis. This review analyzes the efficacy and limitations of HBOT in orthopedic and rheumatologic patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28786258

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


  2 in total

1.  Platet Rich Plasma or Hyperbaric Oxygen Therapy as callus accellerator in aseptic tibial non union. Evaluate of outcomes.

Authors:  Giuseppe Rollo; Enrico Maria Bonura; Gabriele Falzarano; Michele Bisaccia; Julio Ribes Iborra; Predrag Grubor; Marco Filipponi; Paolo Pichierri; Philip Hitov; Danilo Leonetti; Valentina Russi; Walter Daghino; Luigi Meccariello
Journal:  Acta Biomed       Date:  2020-11-10

Review 2.  The role of physiotherapy in fibromyalgia: Current and future perspectives.

Authors:  Mateus Dias Antunes; Amélia Pasqual Marques
Journal:  Front Physiol       Date:  2022-08-16       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.